Loading chat...
NY A11279
Bill
Status
7/25/2018
Primary Sponsor
Patricia Fahy
Click for details
AI Summary
-
Requires physicians and authorized practitioners to test cancer patients for dihydropyrimidine dehydrogenase deficiency before administering fluoropyrimidine or other antimetabolite treatments.
-
Mandates that insurance policies providing medical coverage and cancer chemotherapy treatment coverage must include coverage for dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrimidine or antimetabolite treatment.
-
Applies coverage requirements to medical expense indemnity corporations, hospital service corporations, and health service corporations in addition to standard insurance policies.
-
Requires the Department of Social Services to establish standards and guidelines for providing dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program.
-
Takes effect 120 days after becoming law, with authority for necessary rule and regulation amendments to be completed immediately.
Legislative Description
Requires dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrmidine or other antimetabolite treatment; requires policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; provides for dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program.
Last Action
referred to health
7/25/2018